***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: Eight studies were identified but only seven trials enrolling 1410 preterm infants were located. There was no significant difference detected in neonatal mortality or neurodevelopmental outcome at two years between infants treated with ethamsylate and controls. Infants treated with ethamsylate had significantly less intraventricular haemorrhage than controls at < 31 weeks (typical RR 0.63, 95% CI 0.47 to 0.86) and < 35 weeks gestation (typical RR 0.77, 0.65 to 0.92). There was also a significant reduction in grade 3 and 4 intraventricular haemorrhage when all infants < 35 weeks gestation (typical RR 0.67, 95% CI 0.49 to 0.94) were analysed as a single group, but not for the group of infants < 32 weeks alone. There was a reduction in symptomatic patent ductus arteriosus at < 31 weeks gestation (typical RR 0.32, 95% CI 0.12 to 0.87). There were no adverse effects of ethamsylate identified from this systematic review. Preterm infants treated with ethamsylate showed no reductions in mortality or neurodevelopmental impairment despite the reduction in any grade of intraventricular haemorrhage seen in infants < 35 weeks gestation.
Output:

A total of seven studies with 1410 preterm infants were included in this review. Most of these initial studies were conducted between 1980 and 1990. Preterm infants treated with ethamsylate had similar outcomes with respect to death and disability at the age of two years when compared to infants who were treated with a placebo. Infants born less than 35 weeks gestation appeared to have less intraventricular haemorrhage when treated with ethamsylate compared to controls, however this did not lead to improved developmental outcome in later childhood. There were no adverse effects noted with ethamsylate treatment. Based on these results, routine use of ethamsylate for prematurely born infants to prevent intraventricular haemorrhage cannot be recommended. It is highly unlikely that any further trials will be conducted to explore this clinical question.